Coloplast A/S
CLPBFOTCHealthcare● Active
$57.56
$-0.08(-0.14%)
Market Cap$11.9B
P/E Ratio—
52W High$100
52W Low$57.28
Coloplast A/S (CLPBF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLPBF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
$0.95
Est. $0.91 · +4.5%
Revenue
$1.09B
Est. $1.09B · +0.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
CLPBF reports quarterly as a OTC-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | $0.96 | — | — | — | $1.11B | — |
| ▲ Q2 FY2026 | May 12, 2026 | $0.91 | $0.95 | +4.5% | $1.09B | $1.09B | +0.1% |
| ▲ Q1 FY2026 | Feb 6, 2026 | $0.96 | $0.99 | +3.5% | $1.11B | $1.12B | -1.3% |
| ▼ Q3 FY2025 | Aug 19, 2025 | $0.83 | $0.56 | -32.3% | $1.10B | $1.10B | -0.5% |
| ▼ Q2 FY2025 | May 6, 2025 | $0.67 | $0.65 | -3.1% | $1.02B | $1.09B | -6.1% |
| ▼ Q1 FY2025 | Feb 4, 2025 | $0.89 | $0.68 | -24.0% | $0.97B | $0.90B | +7.5% |
| ▼ Q4 FY2024 | Nov 5, 2024 | $5.97 | $5.84 | -2.2% | $1.02B | $0.92B | +10.9% |
| ▼ Q3 FY2024 | Aug 20, 2024 | $5.82 | $5.66 | -2.8% | $0.99B | $0.96B | +2.9% |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
$0.96
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
$0.95
EPS Est.
$0.91
EPS Surpr.
+4.5%
Revenue
$1.09B
Q1 FY2026
Feb 6, 2026Beat
EPS Actual
$0.99
EPS Est.
$0.96
EPS Surpr.
+3.5%
Revenue
$1.11B
Q3 FY2025
Aug 19, 2025Miss
EPS Actual
$0.56
EPS Est.
$0.83
EPS Surpr.
-32.3%
Revenue
$1.10B
Q2 FY2025
May 6, 2025Miss
EPS Actual
$0.65
EPS Est.
$0.67
EPS Surpr.
-3.1%
Revenue
$1.02B
Q1 FY2025
Feb 4, 2025Miss
EPS Actual
$0.68
EPS Est.
$0.89
EPS Surpr.
-24.0%
Revenue
$0.97B
Q4 FY2024
Nov 5, 2024Miss
EPS Actual
$5.84
EPS Est.
$5.97
EPS Surpr.
-2.2%
Revenue
$1.02B
Q3 FY2024
Aug 20, 2024Miss
EPS Actual
$5.66
EPS Est.
$5.82
EPS Surpr.
-2.8%
Revenue
$0.99B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $12.84 | $13.08 | $13.29 | 1 |
| Q3 FY2026 | $6.03 | $6.14 | $6.24 | 1 |
| Q2 FY2026 | $6.15 | $6.27 | $6.37 | 1 |
| Q1 FY2026 | $5.80 | $5.91 | $6.01 | 1 |
| Q4 FY2025 | $5.98 | $6.09 | $6.19 | 1 |
| Q3 FY2025 | $5.89 | $6.00 | $6.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $7.4B | $7.5B | $7.5B | 7 |
| Q3 FY2026 | $7.3B | $7.4B | $7.5B | 8 |
| Q2 FY2026 | $7.2B | $7.3B | $7.4B | 8 |
| Q1 FY2026 | $7.0B | $7.1B | $7.1B | 6 |
| Q4 FY2025 | $7.0B | $7.1B | $7.2B | 9 |
| Q3 FY2025 | $6.9B | $7.0B | $7.2B | 11 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +4.5% | $63.28 | $63.28 | +0.00% |
| ▲ Q1 FY2026 | Feb 6, 2026 | +3.5% | $85.00 | $80.00 | -5.88% |
| ▼ Q3 FY2025 | Aug 19, 2025 | -32.3% | $93.55 | $93.70 | +0.16% |
| ▼ Q2 FY2025 | May 6, 2025 | -3.1% | $106.25 | $106.25 | +0.00% |
| ▼ Q1 FY2025 | Feb 4, 2025 | -24.0% | $113.09 | $113.09 | +0.00% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -2.2% | $130.00 | $130.00 | +0.00% |
| ▼ Q3 FY2024 | Aug 20, 2024 | -2.8% | $133.55 | $128.60 | -3.71% |
| ▼ Q2 FY2024 | May 7, 2024 | -4.5% | $120.25 | $120.88 | +0.52% |
Q2 FY2026+0.00%
Report Date
May 12, 2026
EPS Beat/Miss
+4.5%
Price Before
$63.28
Price After
$63.28
Q1 FY2026-5.88%
Report Date
Feb 6, 2026
EPS Beat/Miss
+3.5%
Price Before
$85.00
Price After
$80.00
Q3 FY2025+0.16%
Report Date
Aug 19, 2025
EPS Beat/Miss
-32.3%
Price Before
$93.55
Price After
$93.70
Q2 FY2025+0.00%
Report Date
May 6, 2025
EPS Beat/Miss
-3.1%
Price Before
$106.25
Price After
$106.25
Q1 FY2025+0.00%
Report Date
Feb 4, 2025
EPS Beat/Miss
-24.0%
Price Before
$113.09
Price After
$113.09
Q4 FY2024+0.00%
Report Date
Nov 5, 2024
EPS Beat/Miss
-2.2%
Price Before
$130.00
Price After
$130.00
Q3 FY2024-3.71%
Report Date
Aug 20, 2024
EPS Beat/Miss
-2.8%
Price Before
$133.55
Price After
$128.60
Q2 FY2024+0.52%
Report Date
May 7, 2024
EPS Beat/Miss
-4.5%
Price Before
$120.25
Price After
$120.88
Avg Beat Reaction-2.94%
Avg Miss Reaction-0.51%
Beat Rate2 / 8 quarters
Largest Move-5.88% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLPBF ends December
Coloplast A/S (CLPBF) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $0.95 — beating the analyst consensus of $0.91 by +4.5%. CLPBF has beaten EPS estimates for 2 consecutive quarters. The next CLPBF earnings date is expected around September 1, 2026.
Each quarter, investors track CLPBF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLPBF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLPBF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLPBF earnings · 5 questionsColoplast A/S's next earnings report is expected around September 1, 2026. CLPBF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLPBF historically reports after market close (AMC).
CLPBF earnings datewhen is CLPBF earningsCLPBF next earnings datewhen does CLPBF report earningsCLPBF earnings calendar
▸ Source: FMP · Coloplast A/S SEC filings · US GAAP · Coloplast A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026